Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,369 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.
Hu ZY, Yan M, Xiong H, Ran L, Zhong J, Luo T, Sun T, Xie N, Liu L, Yang X, Xiao H, Li J, Liu B, Ouyang Q. Hu ZY, et al. Among authors: xiao h. BMC Med. 2023 Jun 26;21(1):226. doi: 10.1186/s12916-023-02943-2. BMC Med. 2023. PMID: 37365596 Free PMC article. Clinical Trial.
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.
Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, Song Y, Hao C, Chen Z, Orlandi A, Ishii N, Takabe K, Franceschini G, Ricci F, Verschraegen C, Liu Z, Zhang M, Lv H, Liu L, Yang X, Xiao H, Gao Z, Li X, Dong F, Chen X, Qiao J, Zhang G. Yan M, et al. Among authors: xiao h. Lancet Oncol. 2022 Mar;23(3):353-361. doi: 10.1016/S1470-2045(21)00716-6. Epub 2022 Jan 31. Lancet Oncol. 2022. PMID: 35085506 Clinical Trial.
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody.
Liu B, Xie N, Tian C, Feng R, Hu ZY, Li J, Liu L, Xiao H, Yang X, Zeng M, Wu H, Lu J, Gao J, Hu X, Cao M, Shui Z, Tang Y, Wu T, Ouyang Q. Liu B, et al. Among authors: xiao h. Breast. 2023 Dec;72:103597. doi: 10.1016/j.breast.2023.103597. Epub 2023 Nov 1. Breast. 2023. PMID: 37944341 Free PMC article.
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial.
Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, Song Y, Hao C, Chen Z, Liu Z, Lv H, Zhang M, Liu L, Yang X, Xiao H, Gao Z, Li X, Dong F, Zhang L, Dong D, Chen X, Qiao J, Zhang G, Zeng H, Wang J, Sun H, Feng Y, Chen Y, Xia F. Yan M, et al. Among authors: xiao h. EClinicalMedicine. 2024 Sep 20;76:102837. doi: 10.1016/j.eclinm.2024.102837. eCollection 2024 Oct. EClinicalMedicine. 2024. PMID: 39380967 Free PMC article.
10,369 results
You have reached the last available page of results. Please see the User Guide for more information.